Search

Your search keyword '"Barentsz, J O"' showing total 220 results
Start Over Author "Barentsz, J O"
220 results on '"Barentsz, J O"'

5. Bladder

Author

Müller-Lisse, U. G., Heuck, A. F., Barentsz, J. O., Baert, A. L., editor, Sartor, K., editor, Youker, J. E., editor, Heuck, Andreas, editor, and Reiser, Maximilian, editor

Published
2000
Full Text
View/download PDF

20. Bladder

Author

Müller-Lisse, U. G., primary, Heuck, A. F., additional, and Barentsz, J. O., additional

Published
2000
Full Text
View/download PDF

21. De FUTURE trial; een multicenter RCT naar MRI-geleide prostaatbiopten: Vergelijking van drie technieken van target biopten en vergelijking met systematische biopten

Author

MS Urologische Oncologie, Wegelin, O., Exterkate, L., Barentsz, J. O., van der Leest, M. G., Kelder, J. C., Kummer, J. A., Vreuls, W., de Bruin, P. C., de Vocht, T. F., Nuininga, J. E., Bosch, J. L.H.R., Somford, D. M., van Melick, H. H.E., MS Urologische Oncologie, Wegelin, O., Exterkate, L., Barentsz, J. O., van der Leest, M. G., Kelder, J. C., Kummer, J. A., Vreuls, W., de Bruin, P. C., de Vocht, T. F., Nuininga, J. E., Bosch, J. L.H.R., Somford, D. M., and van Melick, H. H.E.

Published
2019

29. Diffusion-weighted imaging with low b factors in prostatic cancer

Author

Rahmouni, A, Jelali, M, Ruel, L, Bouanane, M, Brugières, P, Kobeiter, H, Luciani, A, Heijmink, S W T P J, van Moerkerk, H, Fütterer, J J, Scheenen, T W J, Hulsbergen-v d Kaa, C A, Witjes, J A, Blickman, J G, Barentsz, J O, Takahashi, S, Kaa, C A Hulsbergen-v.d., Vilanova, J C, Barceló, J, Herrero, J Camps, Navarro, M Forment, Martí, M T Loret, Rubio, C Martinez, Selma, V Ricart, Crivellé, M Sentís, Noguera, P J Gonzalez, Rizzatto, G, Chersevani, R, Ralleigh, G, Ley, S, Schenk, J, Edelhäuser, M, Zaporozhan, J, Kulozik, A, Haufe, E, Tröger, J, Kauczor, H-U, Matzek, W K, Ba-Ssalamah, A, Pinker, K, Zacherl, J, Püspök, A, Schima, W, Vandecaveye, V, De Keyzer, F, Nuyts, S, Poorten, V Vander, Delaere, P, Hermans, R, Giesel, F L, von Tengg-Kobligk, H, Jellinek, D A, Levy, D, Miller, B A, Griffiths, P D, Wilkinson, I D, Dobson, M J, Rudralingam, V, Ng, C S, Faria, S C, Yao, J C, Wang, X, Charnsangavej, C, Sandomenico, F, Catalano, O, Raso, M Mattace, Vallone, P, Siani, A, Wenaden, A E T, Alijani, M, Hughes, J, Barber, S, Chin-Aleong, J, Dorudi, S, Rockall, A, and Reznek, R H

Subjects
Symposium, Article
Published
2005

30. MRI-guided needle localisation of suspicious breast lesions: results of a freehand technique

Author

van den Bosch, M A A J, Daniel, B L, Jeffrey, S S, Ikeda, D M, Veltman, J, Boetes, C, Kok, T, Obdeijn, I M, Manoliu, R, Blickman, J G, Barentsz, J O, Huisman, H J, Rizzo, S, Preda, L, Villa, G, Bazzi, L, Cassano, E, Bellomi, M, Dicken, V, Bornemann, L, Kuhnigk, J-M, Krass, S, Wormanns, D, Peitgen, O, Schmidt, G P, de Geus-Oei, L F, Pieters, G F F M, Bonenkamp, J J, Mudde, A H, Corstens, F H M, Oyen, W J G, Fütterer, J J, Th van Lin, E N J, Heijmink, S W T P J, van der Vight, L P, Visser, A G, Sonke, J-J, Remeijer, P, Betgen, A, Lebesque, J, Jaffray, D, Herk, M V, Schueller, G, Prokesch, R, Schueller-Weidekamm, C, Schima, W, Bent, C L, Sahdev, A, Wenaden, A, Sohaib, S A, Rockall, A, Reznek, R H, Hughes, J L, Wenaden, A E T, Shepherd, J H, Anderson, K E, Hewitt, M J, Wilkinson, N, Swift, S E, Weston, M J, and Spencer, J A

Subjects
Symposium, Article
Published
2005

33. Prostate cancer: staging using imaging

Author

Engelbrecht, M. R., Barentsz, J. O., Jager, G. J., van der Graaf, M., Heerschap, A., Sedelaar, J. P., Aarnink, R. G., de la Rosette, J. J., and Other departments

Subjects
Ultrasonographic tissue discrimination. Automatic detection of prostate carcinoma, Biomedische Magnetische Resonantie, Echografische beeldanalyse. Geautomatiseerde opsporing van prostaatcarcinoon, Biomedical Magnetic Resonance
Abstract

Item does not contain fulltext

Published
2000

35. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue

Author

Heerschap, A., Jager, G. J., van der Graaf, M., Barentsz, J. O., de la Rosette, J. J., Oosterhof, G. O., Ruijter, E. T., Ruijs, S. H., and Other departments

Abstract

Recently the potential of magnetic resonance (MR) methods for non-invasive diagnosis and therapy evaluation of prostate cancer has improved substantially. In this study proton MR spectroscopy (1H MRS) was explored for the detection of cancer in the prostate. Patients and Methods: Employing an endorectal probe localized 1H MRS and contrast enhanced MR imaging was performed on the prostate of healthy volunteers and of patients with benign prostatic hyperplasia (BPH) and/or prostate cancer (PCa). 1H MR spectra of the human prostate showed major signals for citrate, creatine and choline compounds. For cancer tissue the average citrate/choline signal ratio was significantly lower than for BPH and non-cancerous peripheral and central zone tissue, but individual ratios overlapped with ratios for normal central zone and BPH tissue. Low citrate/choline ratios in tumour tissue correspond with early MR contrast enhancement. 1H MRS has potential for non-invasive detection and follow-up of tumours in the prostate

Published
1997

40. Preliminary results of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer

Author

Jager, G. J., Barentsz, J. O., de la Rosette, J. J., Rosenbusch, G., and Other departments

Abstract

To evaluate the effectiveness of endorectal surface coil (ERC) magnetic resonance imaging (MRI) in the local staging of adenocarcinoma of the prostate (ACP). A total of 23 patients who were considered candidates for radical prostatectomy because of clinically localized ACP were examined by ERC-MRI. All patients underwent laparoscopic or open lymph-node dissection prior to surgery. Four patients had positive lymph nodes at operation. A total of 19 underwent radical prostatectomy, allowing comparison of the MRI data with the surgical pathologic findings. Twelve patients had extraglandular spread of ACP (T3) and 7 had locally confined ACP (T2). ERC-MRI predicted correctly a T3 tumor in 10 of 12 cases and a T2 tumor in 4 of 7 cases. ERC-MRI was 74% accurate in differentiating T2 from T3 tumor. Three cases of overestimation were in studies with poor image quality because of bowel movement motion artifacts. ERC-MRI was found to be a sensitive modality in staging clinically localized ACP

Published
1994

41. Assessment of early vascular effects of the angiogenesis inhibitor sunitinib (SU) in renal cell carcinoma (RCC) by dynamic contrast enhanced MRI (DCE-MRI) and diffusion weight MRI (DWI) at 3 tesla (T).

Author

Desar, I., primary, Van Laarhoven, H., additional, Hambrock, T., additional, Ter Voert, E., additional, Van Der Graaf, W., additional, Van Spronsen, D., additional, Barentsz, J. O., additional, Heerschap, A., additional, and Van Herpen, C., additional

Published
2010
Full Text
View/download PDF

45. Magnetic resonance imaging.

Author

Bassi, PierFrancesco, Pagano, Francesco, and Barentsz, J O

Abstract

In the Western world, the most frequently encountered pelvic diseases are neoplasms. Urinary bladder and prostate cancer are the most common diseases of the male pelvis seen by radiologists. This paper focuses on these diseases. MR (magnetic resonance) imaging is the most promising technique in visualizing these tumours, and the emphasis of this paper is on this imaging modality. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

46. Imaging of the Male Pelvis.

Author

Hodler, J., Schulthess, G. K., Zollikofer, Ch. L., Barentsz, J. O., Wagner, B. J., and Abouh-Bieh, E.

Abstract

Prostate cancer continues to be the leading cancer among American men, with 184,500 new cases annually [1]. It has been estimated that 39,200 men died of prostate cancer in the U.S.A. in 1998. This makes prostate cancer the second cause of cancer-related death in men [2, 3]. Furthermore, the probability of developing prostate cancer from birth to death is 20% [3]. Treatment selection is dependent on patient age and health, cancer stage and grade, morbidity and mortality of treatment, as well as patient and physician preference. The mainstay for organ-confined disease is either radical surgery or curative radiotherapy [4, 5]. This is only considered an option in the absence of seminal vesicle infiltration (SVI), extension through the prostatic capsule (extracapsular extension, ECE) or metastatic disease. Therefore, the purpose of staging is the possible detection of extraprostatic disease. Clinical staging by digital rectal examination (DRE) and prostate specific antigen (PSA) remains as yet inaccurate. Imaging modalities such as transrectal ultrasound (TRUS) and magnetic resonance (MR) imaging can be used to increase staging accuracy. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results